# US 2002/0055666 A1 · Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055666 A1
- Document ID: US20020055666A1
- Status: Published application
- Kind: A1
- Application number: 09/865,195
- Filed: 2001-05-24
- Published: 2002-05-09
- Earliest claimed: 1999-11-12
- Inventors: William L. Hunter; David M. Gravett; Richard T. Liggins; Troy A.E. Loss; Arpita Maiti; Philip M. Toleikis
- Web page: https://patentgrep.com/patent/US20020055666A1

## CPC

- A61N 5/1027: {Interstitial radiation therapy}
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 51/1282: {Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents}
- A61P 35/00: Antineoplastic agents
- A61N 2005/1023: {Means for creating a row of seeds, e.g. spacers}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

## Claims

### Claim 1

A therapeutic device, comprising a device which locally administers radiation, and a cell-cycle inhibitor.

### Claim 2 (depends on 1)

The device according to claim 1 wherein said device is a radioactive stent.

### Claim 3 (depends on 1)

The device according to claim 1 wherein said device is a radioactive rod.

### Claim 4 (depends on 1)

The device according to claim 1 wherein said device is a radioactive disk.

### Claim 5 (depends on 1)

The device according to claim 1 wherein said device is a radioactive seed.

### Claim 6 (depends on 1)

The device according to claim 1 wherein said device is a radioactive suture.

### Claim 7 (depends on 1)

The device according to claim 1 wherein said device further comprises a polymer.

### Claim 8 (depends on 7)

The device according to claim 7 wherein said cell-cycle inhibitor is released by said polymer.

### Claim 9 (depends on 1)

The device according to claim 1 wherein said radiation is released from a polymer.

### Claim 10 (depends on 7, 9)

The device according to claim 7 or 9 wherein said polymer is a non-biodegradable polymer.

### Claim 11 (depends on 7, 9)

The device according to claim 7 or 9 wherein said polymer is a biodegradable polymer.

### Claim 12 (depends on 7, 9)

The device according to claim 7 or 9 wherein said polymer is poly (ethylene-vinyl acetate, polyurethane, polyester, poly (caprolactone), poly (lactic acid), poly (glycolic acid) and copolymers thereof.

### Claim 13 (depends on 7)

The device according to claim 7 wherein said polymer comprises a copolymer of poly (caprolactone) and poly (lactic acid).

### Claim 14 (depends on 7)

The device according to claim 7 wherein said polymer comprises MePEG.

### Claim 15 (depends on 1)

The device according to claim 1 wherein said radiation is from a radioactive source selected from the group consisting of activity I125, Pd103, Au198 and Ir192; Co60, Cs137, and Ru106.

### Claim 16 (depends on 1)

The device according to claim 1 wherein said cell-cycle inhibitor is a taxane.

### Claim 17 (depends on 1)

The device according to claim 1 wherein said cell-cycle inhibitor is a topoisomerase inhibitor.

### Claim 18 (depends on 1)

The device according to claim 1 wherein said cell-cycle inhibitor is an alkylating agent, anti-metabolite, or, vinca alkaloid.

### Claim 19

A therapeutic device, comprising:
a radioactive source sized to be positioned into the tissue of a patient adjacent to a site to be treated by locally administered radiation from the radioactive source; and
a cell-cycle inhibitor positioned adjacent to the radioactive source.

### Claim 20 (depends on 19)

The device according to claim 19 further including a carrier member supporting the radioactive source.

### Claim 21 (depends on 20)

The device according to claim 20 wherein the carrier member is a suture.

### Claim 22 (depends on 21)

The device according to claim 21 wherein the radioactive source is disposed within the suture.

### Claim 23 (depends on 22)

The device according to claim 22 wherein the radioactive source comprises a plurality of radioactive seeds, and the seeds are positioned at locations along a length of the suture.

### Claim 24 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is positioned within the suture.

### Claim 25 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is positioned within the suture by being absorbed by the suture prior to positioning of the suture in the tissue.

### Claim 26 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is carried by a carrier material positioned one of within the suture or on an outer surface of the suture, and the carrier material is a material selected to release a cell-cycle inhibitor when the suture is within the tissue.

### Claim 27 (depends on 26)

The device according to claim 26 wherein the material selected for the carrier material is a polymer.

### Claim 28 (depends on 26)

The device according to claim 26 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the suture in the tissue.

### Claim 29 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is carried by a carrier material positioned within the suture or on an outer surface of the suture, and the carrier material is a material selected to elute a cell-cycle inhibitor when the suture is within the tissue.

### Claim 30 (depends on 21)

The device according to claim 21 wherein the suture has at least a portion of the suture comprised of a material that carries a cell-cycle inhibitor.

### Claim 31 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is carried by the suture, and the suture is a material selected to release a cell-cycle inhibitor when the suture is within the tissue.

### Claim 32 (depends on 31)

The device according to claim 31 wherein the material selected for the carrier member is a polymer.

### Claim 33 (depends on 31)

The device according to claim 31 wherein a cell-cycle inhibitor is carried by the suture by being absorbed by the suture prior to positioning of the suture in the tissue.

### Claim 34 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is carried by the suture, and the suture is a material selected to elute a cell-cycle inhibitor when the suture is within the tissue.

### Claim 35 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is positioned on an outer surface of the suture prior to positioning of the suture in the tissue.

### Claim 36 (depends on 21)

The device according to claim 21 wherein the suture has an outer member positioned at least partially about an outer surface of the suture prior to positioning of the suture in the tissue, and a cell-cycle inhibitor is carried by the outer member.

### Claim 37 (depends on 36)

The device according to claim 36 wherein the outer member is a coating at least partially covering the outer surface of the suture.

### Claim 38 (depends on 37)

The device according to claim 37 wherein the coating is a polymeric material and a cell-cycle inhibitor is within the polymeric material.

### Claim 39 (depends on 37)

The device according to claim 37 wherein the outer member is a material selected to release a cell-cycle inhibitor when the suture is within the tissue.

### Claim 40 (depends on 39)

The device according to claim 39 wherein the material selected for the outer member is a polymer.

### Claim 41 (depends on 37)

The device according to claim 37 wherein the outer member is a material selected to elute a cell-cycle inhibitor when the suture is within the tissue.

### Claim 42 (depends on 21)

The device according to claim 21 wherein a cell-cycle inhibitor is one of chemically linked to or coated on the radioactive suture.

### Claim 43 (depends on 19)

The device according to claim 19 wherein the radioactive source is a radioactive wire.

### Claim 44 (depends on 43)

The device according to claim 43 wherein a cell-cycle inhibitor is positioned on an outer surface of the wire.

### Claim 45 (depends on 43)

The device according to claim 43 wherein a cell-cycle inhibitor is positioned on an outer surface of the wire prior to positioning of the wire in the tissue.

### Claim 46 (depends on 43)

The device according to claim 43 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of the wire, and the carrier material is a material selected to release a cell-cycle inhibitor when the wire is within the tissue.

### Claim 47 (depends on 46)

The device according to claim 46 wherein the material selected for the carrier material is a polymer.

### Claim 48 (depends on 46)

The device according to claim 46 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the wire in the tissue.

### Claim 49 (depends on 43)

The device according to claim 43 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of the wire, and the carrier material is a material selected to elute a cell-cycle inhibitor when the wire is within the tissue.

### Claim 50 (depends on 43)

The device according to claim 43 wherein the wire has an outer member positioned at least partially about an outer surface of the wire prior to positioning of the wire in the tissue, and a cell-cycle inhibitor is carried by the outer member.

### Claim 51 (depends on 50)

The device according to claim 50 wherein the outer member is a coating at least partially covering the outer surface of the wire.

### Claim 52 (depends on 51)

The device according to claim 51 wherein the coating is a polymeric material and a cell-cycle inhibitor is within the polymeric material.

### Claim 53 (depends on 51)

The device according to claim 51 wherein the outer member is a material selected to release a cell-cycle inhibitor when the wire is within the tissue.

### Claim 54 (depends on 53)

The device according to claim 53 wherein the material selected for the outer member is a polymer.

### Claim 55 (depends on 50)

The device according to claim 50 wherein the outer member is a material selected to release a cell-cycle inhibitor when the wire is within the tissue.

### Claim 56 (depends on 43)

The device according to claim 43 wherein a cell-cycle inhibitor is one of chemically linked to or coated on the wire.

### Claim 57 (depends on 19)

The device according to claim 19 wherein the radioactive source comprises a plurality of radioactive seeds.

### Claim 58 (depends on 57)

The device according to claim 57 wherein a cell-cycle inhibitor is positioned on an outer surface of the seeds.

### Claim 59 (depends on 57)

The device according to claim 57 wherein a cell-cycle inhibitor is positioned on an outer surface of the seeds prior to positioning of the seeds in the tissue.

### Claim 60 (depends on 57)

The device according to claim 57 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of each of the seeds, and the carrier material is a material selected to release a cell-cycle inhibitor when the seeds are within the tissue.

### Claim 61 (depends on 60)

The device according to claim 60 wherein the material selected for the carrier member is a polymer.

### Claim 62 (depends on 60)

The device according to claim 60 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the seeds in the tissue.

### Claim 63 (depends on 57)

The device according to claim 57 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of each of the seeds, and the carrier material is a material selected to elute a cell-cycle inhibitor when the seeds are within the tissue.

### Claim 64 (depends on 57)

The device according to claim 57 further including a spacer positioned adjacent to one of the plurality of radioactive seeds.

### Claim 65 (depends on 64)

The device according to claim 64 wherein a cell-cycle inhibitor is carried by the spacer.

### Claim 66 (depends on 65)

The device according to claim 65 wherein the spacer is a material selected to release a cell-cycle inhibitor when within the tissue.

### Claim 67 (depends on 66)

The device according to claim 66 wherein the material selected for the spacer is a polymer.

### Claim 68 (depends on 65)

The device according to claim 65 wherein a cell-cycle inhibitor is carried by the spacer by being absorbed by the spacer prior to positioning of the spacer in the tissue.

### Claim 69 (depends on 65)

The device according to claim 65 wherein the spacer is a material selected to elute a cell-cycle inhibitor when within the tissue.

### Claim 70 (depends on 64)

The device according to claim 64 wherein the spacer is a polymeric material and a cell-cycle inhibitor is within the polymeric material.

### Claim 71 (depends on 64)

The device according to claim 64 wherein a cell-cycle inhibitor is positioned on an outer surface of the spacer.

### Claim 72 (depends on 71)

The device according to claim 71 wherein a cell-cycle inhibitor is positioned on the outer surface of the spacer prior to positioning of the spacer in the tissue.

### Claim 73 (depends on 64)

The device according to claim 64 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of the spacer, and the carrier material is a material selected to elute a cell-cycle inhibitor when the spacer are within the tissue.

### Claim 74 (depends on 73)

The device according to claim 73 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the spacer in the tissue.

### Claim 75 (depends on 64)

The device according to claim 64 wherein the seeds and the spacers positioned between the seeds are sized to be received in a catheter for insertion into the tissue.

### Claim 76 (depends on 64)

The device according to claim 64 wherein the spacers are elongated with a length and positioned with a lengthwise orientation extending between the adjacent seeds between which positioned, and the spacer length is selected to position and hold the seeds within the tissue in a desired spatial pattern based upon the radiation pattern desired to be administered to the site to be treated.

### Claim 77 (depends on 57)

The device according to claim 57 further including a spacer positioned between adjacent ones of the plurality of radioactive seeds, the spacers both holding the adjacent seeds spaced apart while in the tissue and holding the plurality of seeds together as part of a continuous thread while being positioned in the tissue.

### Claim 78 (depends on 77)

The device according to claim 77 wherein the spacers are formed from a spacer material having a liquid phase and a solid phase, the spacers being formed using the spacer material in the liquid phase immediately prior to the time of positioning of the seeds into the tissue by placing the liquid phase spacer material between adjacent ones of the seeds and then allowing the spacer material to change to the solid phase to form the continuous thread.

### Claim 79 (depends on 57)

The device according to claim 57 further including a spacer positioned between adjacent ones of the plurality of radioactive seeds, the spacers holding the adjacent seeds spaced apart while in the tissue, the spacers being a spacer material having a liquid phase and a solid phase, the spacers being formed using the spacer material in the liquid phase immediately prior to the time of positioning of the seeds into the tissue by placing the liquid phase spacer material between adjacent ones of the seeds and then allowing the spacer material to change to the solid phase prior to positioning of the spacers in the tissue.

### Claim 80 (depends on 79)

The device according to claim 79 for use with a catheter, wherein the seeds are positioned in the catheter in spaced apart relation and the spacer material in the liquid phase is placed between adjacent ones of the seeds and then allowed to change to the solid phase, after changing to the solid phase and without removing the seeds and the spacers from the catheter, the seeds and the spacers being positioned in the catheter in a molded state ready for positioning in the tissue using the catheter.

### Claim 81 (depends on 80)

The device according to claim 80 wherein after the spacer material has been allowed to change to the solid phase, the seeds and the spacers are in the form of a continuous thread holding the plurality of seeds together for positioning in the tissue and holding the adjacent seeds spaced apart while in the tissue.

### Claim 82 (depends on 80)

The device according to claim 80 wherein the spacer material is in the liquid phase when heated to a liquid phase temperature above a body temperature of the patient, and in the solid phase when allowed to cool to a solid phase temperature below the liquid phase temperature.

### Claim 83 (depends on 57)

The device according to claim 57 wherein a cell-cycle inhibitor is one of chemically linked to or coated on the seeds.

### Claim 84 (depends on 19)

The device according to claim 19 wherein the radioactive source comprises at least one radioactive seed and the seed has an outer member positioned at least partially about an outer surface of the seed prior to positioning of the seed in the tissue, and wherein a cell-cycle inhibitor is carried by the outer member.

### Claim 85 (depends on 84)

The device according to claim 84 wherein the outer member is a coating at least partially covering the outer surface of the seed.

### Claim 86 (depends on 85)

The device according to claim 85 wherein the coating is a polymeric material and a cell-cycle inhibitor is within the polymeric material.

### Claim 87 (depends on 84)

The device according to claim 84 wherein the outer member is a material selected to release a cell-cycle inhibitor when the wire is within the tissue.

### Claim 88 (depends on 87)

The device according to claim 87 wherein the material selected for the outer member is a polymer.

### Claim 89 (depends on 84)

The device according to claim 84 wherein the outer member is a material selected to elute a cell-cycle inhibitor when the wire is within the tissue.

### Claim 90 (depends on 84)

The device according to claim 84 wherein a cell-cycle inhibitor is carried by the outer member by being absorbed by the outer member prior to positioning of the seeds in the tissue.

### Claim 91 (depends on 19)

The device according to claim 19 wherein the radioactive source comprises at least one radioactive seed, and wherein a cell-cycle inhibitor is one of chemically linked to or coated on the seed.

### Claim 92

A therapeutic device, comprising:
a radioactive source sized to be positioned into a pre-existing or created body cavity of a patient adjacent to a site to be treated by locally administered radiation from the radioactive source; and
a cell-cycle inhibitor positioned adjacent to the radioactive source.

### Claim 93 (depends on 92)

The device according to claim 92 wherein the radioactive source is a radioactive stent.

### Claim 94 (depends on 93)

The device according to claim 93 wherein the radioactive source is a radioactive film.

### Claim 95 (depends on 93)

The device according to claim 93 wherein the stent is formed of a carrier material and the carrier material carries a cell-cycle inhibitor, the carrier material being a material selected to release a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 96 (depends on 95)

The device according to claim 95 wherein the carrier material is a polymer.

### Claim 97 (depends on 92)

The device according to claim 92 further including a stent sized to be positioned in the body cavity, the stent being formed of a carrier material which carries a cell-cycle inhibitor, the carrier material being a material selected to release a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 98 (depends on 97)

The device according to claim 97 wherein the carrier material is a polymer.

### Claim 99 (depends on 93)

The device according to claim 93 wherein a cell-cycle inhibitor is positioned on an outer surface of the stent.

### Claim 100 (depends on 93)

The device according to claim 93 wherein a cell-cycle inhibitor is positioned on an outer surface of the stent prior to positioning of the stent in the body cavity.

### Claim 101 (depends on 93)

The device according to claim 93 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of the stent, and the carrier material is a material selected to release a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 102 (depends on 93)

The device according to claim 93 wherein the material selected for the carrier material is a polymer.

### Claim 103 (depends on 101)

The device according to claim 101 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the stent in the body cavity.

### Claim 104 (depends on 93)

The device according to claim 93 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of the stent, and the carrier material is a material selected to elute a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 105 (depends on 93)

The device according to claim 93 wherein the stent has an outer member positioned at least partially about an outer surface of the stent prior to positioning of the stent in the body cavity, and a cell-cycle inhibitor is carried by the outer member.

### Claim 106 (depends on 105)

The device according to claim 105 wherein the outer member is a coating at least partially covering the outer surface of the stent.

### Claim 107 (depends on 106)

The device according to claim 106 wherein the coating is a polymeric material and a cell-cycle inhibitor is within the polymeric material.

### Claim 108 (depends on 105)

The device according to claim 105 wherein the outer member is a material selected to release a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 109 (depends on 108)

The device according to claim 108 wherein the material selected for the outer member is a polymer.

### Claim 110 (depends on 108)

The device according to claim 108 wherein a cell-cycle inhibitor is carried by the outer member by being absorbed by the outer member prior to positioning of the stent in the body cavity.

### Claim 111 (depends on 105)

The device according to claim 105 wherein the outer member is a material selected to elute a cell-cycle inhibitor when the stent is within the body cavity.

### Claim 112 (depends on 93)

The device according to claim 93 wherein a cell-cycle inhibitor is one of chemically linked to or coated on the stent.

### Claim 113 (depends on 92)

The device according to claim 92 wherein the radioactive source comprises a plurality of radioactive seeds.

### Claim 114 (depends on 113)

The device according to claim 113 wherein a cell-cycle inhibitor is positioned on an outer surface of the seeds.

### Claim 115 (depends on 113)

The device according to claim 113 wherein a cell-cycle inhibitor is positioned on an outer surface of the seeds prior to positioning of the seeds in the body cavity.

### Claim 116 (depends on 113)

The device according to claim 113 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of each of the seeds, and the carrier material is a material selected to release a cell-cycle inhibitor when the seeds are in the body cavity.

### Claim 117 (depends on 116)

The device according to claim 116 wherein the material selected for the carrier member is a polymer.

### Claim 118 (depends on 116)

The device according to claim 116 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to positioning of the seeds in the body cavity.

### Claim 119 (depends on 113)

The device according to claim 113 wherein a cell-cycle inhibitor is carried by a carrier material positioned on an outer surface of each of the seeds, and the carrier material is a material selected to elute a cell-cycle inhibitor when the seeds are in the body cavity.

### Claim 120 (depends on 113)

The device according to claim 113 wherein a cell-cycle inhibitor is one of chemically linked to or coated on the seeds.

### Claim 121

A therapeutic device, comprising:
a radioactive source;
a capsule containing the radioactive source, the capsule being sized to be positioned into a pre-existing or created body cavity of a patient adjacent to a site to be treated by locally administered radiation from the radioactive source; and
a cell-cycle inhibitor.

### Claim 122 (depends on 121)

The device according to claim 121 wherein the radioactive source comprises a plurality of radioactive seeds.

### Claim 123 (depends on 121)

The device according to claim 121 wherein a cell-cycle inhibitor is positioned on an outer surface of the capsule.

### Claim 124 (depends on 123)

The device according to claim 123 wherein a cell-cycle inhibitor is positioned on the outer surface of the radioactive source prior to positioning of the radioactive source in the capsule.

### Claim 125 (depends on 121)

The device according to claim 121 wherein a cell-cycle inhibitor is positioned within the capsule adjacent to the radioactive source.

### Claim 126 (depends on 121)

The device according to claim 121 wherein a cell-cycle inhibitor is carried by a carrier material selected to release a cell-cycle inhibitor when the capsule is in the body cavity.

### Claim 127 (depends on 126)

The device according to claim 126 wherein the carrier material is positioned on an outer surface of the capsule.

### Claim 128 (depends on 126)

The device according to claim 126 wherein the carrier material is positioned on an outer surface of the capsule prior to positioning of the radioactive source in the capsule.

### Claim 129 (depends on 126)

The device according to claim 126 wherein the carrier material is positioned within the capsule adjacent to the radioactive source.

### Claim 130 (depends on 126)

The device according to claim 126 wherein the carrier material forms the body of the capsule.

### Claim 131 (depends on 126)

The device according to claim 126 wherein the material selected for the carrier member is a polymer.

### Claim 132 (depends on 126)

The device according to claim 126 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to the capsule being positioning in the body cavity.

### Claim 133 (depends on 121)

The device according to claim 121 wherein a cell-cycle inhibitor is carried by a carrier material selected to elute a cell-cycle inhibitor when the capsule is in the body cavity.

### Claim 134

A therapeutic device, comprising:
a radioactive source;
a body contact member carrying the radioactive source, the body contact member being sized to be positioned against a pre-existing or created surface site of a patient's body to be treated by locally administered radiation from the radioactive source; and
a cell-cycle inhibitor.

### Claim 135 (depends on 134)

The device according to claim 134 wherein the body contact member is a sheet.

### Claim 136 (depends on 134)

The device according to claim 134 for use when the site of the patient's body to be treated is curved, wherein the body contact member is sufficiently flexible to be bent to at least partially approximate the curve of the site.

### Claim 137 (depends on 134)

The device according to claim 134 for use when the site of the patient's body to be treated is curved, wherein the body contact member is contoured to at least partially approximate the curve of the site.

### Claim 138 (depends on 137)

The device according to claim 137 wherein the body contact member is molded to the curve of the site.

### Claim 139 (depends on 134)

The device according to claim 134 wherein the radioactive source comprises a plurality of radioactive wires.

### Claim 140 (depends on 139)

The device according to claim 139 wherein the radioactive wires are arranged about the body contact member in a desired spatial pattern based upon a radiation pattern desired to be administered to the site to be treated.

### Claim 141 (depends on 139)

The device according to claim 139 wherein the radioactive wires are embedded in the body contact member.

### Claim 142 (depends on 139)

The device according to claim 139 wherein the body contact member includes a plurality of spaced apart recesses sized to receive at least partially therein the radioactive wires.

### Claim 143 (depends on 142)

The device according to claim 142 further including a retainer member extending over at least a portion of the recesses and retaining the radioactive wires in the recesses.

### Claim 144 (depends on 143)

The device according to claim 143 wherein the retaining member is a sheet extending over at least a portion of the body contact member and closing at least the portion of the recesses over which the sheet extends.

### Claim 145 (depends on 142)

The device according to claim 142 wherein the body contact member is a flexible film.

### Claim 146 (depends on 145)

The device according to claim 145 wherein the film is scored to form the recesses therein.

### Claim 147 (depends on 139)

The device according to claim 139 wherein the body contact member is a first flexible film and the radioactive wires are one of embedded in, resident on, or retained upon the first film.

### Claim 148 (depends on 147)

The device according to claim 147 wherein the first film is selected of a material which can be cut with one of a scalpel or scissors to a desired shape.

### Claim 149 (depends on 147)

The device according to claim 147 wherein the radioactive wires are positioned in a desired spatial pattern with respect to the first film based upon a radiation pattern desired to be administered to the site to be treated

### Claim 150 (depends on 147)

The device according to claim 147 further including a second flexible film extending over at least a portion of the first film with the radioactive wires being retained between the first and second films.

### Claim 151 (depends on 150)

The device according to claim 150 wherein the first film includes a plurality of spaced apart recesses sized to receive at least partially therein the radioactive wires, and the second film at least partially closes the recesses to retain the radioactive wires therein.

### Claim 152 (depends on 139)

The device according to claim 139 wherein the body contact member is a flexible film with a plurality of spaced apart recesses sized to receive at least partially therein the radioactive wires, and the device further includes at least one retainer member positioned to retain the radioactive wires within the recesses.

### Claim 153 (depends on 134)

The device according to claim 134 wherein the radioactive source comprises a plurality of radioactive seeds.

### Claim 154 (depends on 153)

The device according to claim 153 wherein the radioactive seeds are arranged about the body contact member in a desired spatial pattern based upon a radiation pattern desired to be administered to the site to be treated.

### Claim 155 (depends on 153)

The device according to claim 153 wherein the radioactive seeds are embedded in the body contact member.

### Claim 156 (depends on 153)

The device according to claim 153 wherein the body contact member includes a plurality of spaced apart recesses sized to receive at least partially therein the radioactive seeds.

### Claim 157 (depends on 156)

The device according to claim 156 further including a retainer member extending over at least a portion of the recesses and retaining the radioactive seeds in the recesses.

### Claim 158 (depends on 157)

The device according to claim 157 wherein the retaining member is a sheet extending over at least a portion of the body contact member and closing at least the portion of the recesses over which the sheet extends.

### Claim 159 (depends on 156)

The device according to claim 156 wherein the body contact member is a flexible film.

### Claim 160 (depends on 159)

The device according to claim 159 wherein the film is scored to form the recesses therein.

### Claim 161 (depends on 153)

The device according to claim 153 wherein the body contact member is a first flexible film and the radioactive seeds are one of embedded in, resident on, or retained upon the first film.

### Claim 162 (depends on 161)

The device according to claim 161 wherein the first film is selected of a material which can be cut with one of a scalpel or scissors to a desired shape.

### Claim 163 (depends on 161)

The device according to claim 161 wherein the radioactive seeds are positioned in a desired spatial pattern with respect to the first film based upon a radiation pattern desired to be administered to the site to be treated.

### Claim 164 (depends on 161)

The device according to claim 161 further including a second flexible film extending over at least a portion of the first film with the radioactive seeds being retained between the first and second films.

### Claim 165 (depends on 164)

The device according to claim 164 wherein the first film includes a plurality of spaced apart recesses sized to receive at least partially therein the radioactive seeds, and the second film at least partially closes the recesses to retain the radioactive seeds therein.

### Claim 166 (depends on 153)

The device according to claim 153 wherein the body contact member is a flexible film with a plurality of spaced apart recesses sized to receive at least partially therein the radioactive seeds, and the device further includes at least one retainer member positioned to retain the radioactive seeds within the recesses.

### Claim 167 (depends on 134)

The device according to claim 134 wherein a cell-cycle inhibitor is positioned on an outer surface of the body contact member.

### Claim 168 (depends on 134)

The device according to claim 134 wherein the body contact member includes a carrier material which carries a cell-cycle inhibitor, the carrier material being selected to release a cell-cycle inhibitor when the body contact member is against the site to be treated.

### Claim 169 (depends on 134)

The device according to claim 134 wherein the body contact member includes at least one recess sized to receive at least partially therein the radioactive source.

### Claim 170 (depends on 169)

The device according to claim 169 further including a retainer member extending over at least a portion of the recess and retaining the radioactive source in the recess.

### Claim 171 (depends on 170)

The device according to claim 170 wherein the retaining member is a sheet extending over at least a portion of the body contact member and closing at least the portion of the recess over which the sheet extends.

### Claim 172 (depends on 134)

The device according to claim 134 wherein the body contact member is a flexible film.

### Claim 173 (depends on 172)

The device according to claim 172 wherein the film is scored to form at least one recess therein to receive at least partially therein the radioactive source.

### Claim 174 (depends on 172)

The device according to claim 172 wherein the film has the radioactive sources at least one of embedded in, resident on, or retained upon the film.

### Claim 175 (depends on 174)

The device according to claim 174 wherein the radioactive source is positioned with a desired spatial pattern with respect to the film based upon a radiation pattern desired to be administered to the site to be treated

### Claim 176 (depends on 134)

The device according to claim 134 wherein the body contact member is formed at least in part from a carrier material which carries a cell-cycle inhibitor, the carrier material being selected to release a cell-cycle inhibitor when the body contact member is against the site to be treated.

### Claim 177 (depends on 176)

The device according to claim 176 wherein the material selected for the carrier member is a polymer.

### Claim 178 (depends on 176)

The device according to claim 176 wherein a cell-cycle inhibitor is carried by the carrier material by being absorbed by the carrier material prior to the body contact member being positioned against the site to be treated.

### Claim 179 (depends on 134)

The device according to claim 134 wherein the body contact member is formed at least in part from a carrier material which carries a cell-cycle inhibitor, the carrier material being selected to elute a cell-cycle inhibitor when the body contact member is against the site to be treated.

### Claim 180

A therapeutic device, comprising:
a radioactive source;
a body contact material carrying the radioactive source, the body contact member being applied to a pre-existing or created surface site of a patient's body to be treated by locally administered radiation from the radioactive source; and
a cell-cycle inhibitor.

### Claim 181 (depends on 180)

The device of claim 180 wherein the body contact material is formed from one of a paste, gel, film or spray applied to the site to be treated.

### Claim 182 (depends on 1, 181)

A method for treating cellular proliferation, comprising administering to a patient a therapeutic device according to any one of claims 1 to 181.

### Claim 183

A method for treating cellular proliferation, comprising administering to a patient a cell-cycle inhibitor, and a source of radiation.

### Claim 184 (depends on 183)

The method according to claim 183 wherein said source of radiation is Pd103, Ir192, Co60, Cs137, or Ru106.

### Claim 185 (depends on 183)

The method according to claim 183 wherein said source of radiation is I125.

### Claim 186 (depends on 183)

The method according to claim 183 wherein said cell-cycle inhibitor is paclitaxel, or an analogue or derivative thereof.

### Claim 187 (depends on 183)

The method according to claim 183 wherein said cell-cycle inhibitor is camptothecin, or an analogue or derivative thereof.

### Claim 188 (depends on 183)

The method according to claim 183 wherein said cell cycle inhibitor is formulated along with a polymer.

### Claim 189 (depends on 183)

The method according to claim 183 wherein said source of radiation is formulated along with a polymer.

### Claim 190 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises a non-biodegradable polymer.

### Claim 191 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises a biodegradable polymer.

### Claim 192 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises poly (caprolactone), polyurethane, or, poly (ethylene-co-vinyl acetate).

### Claim 193 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises poly (lactic acid).

### Claim 194 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises a copolymer of poly (caprolactone) and poly (lactic acid).

### Claim 195 (depends on 188, 189)

The method according to claim 188 or 189 wherein said polymer comprises a polyethylene glycol.

### Claim 196 (depends on 183)

The method according to claim 183 wherein said source of radiation is a radioactive stent.

### Claim 197 (depends on 183)

The method according to claim 183 wherein said source of radiation is a radioactive rod.

### Claim 198 (depends on 183)

The method according to claim 183 wherein said source of radiation is a radioactive disk.

### Claim 199 (depends on 183)

The method according to claim 183 wherein said source of radiation is a radioactive seed.

### Claim 200 (depends on 183)

The method according to claim 183 wherein said source of radiation is a radioactive suture.

### Claim 201 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cellular proliferation is due to cancer.

### Claim 202 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cellular proliferation is due to stenosis or restenosis.

### Claim 203 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cellular proliferation is due to an adhesion.

### Claim 204 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cellular proliferation is due to vascular disease.

### Claim 205 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cellular proliferation is due to arthritis.

### Claim 206 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cell-cycle inhibitor or radioactive source is administered close to the surface of the body.

### Claim 207 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cell-cycle inhibitor or radioactive source is administered within a body cavity.

### Claim 208 (depends on 182, 183)

The method according to claim 182 or 183 wherein said cell-cycle inhibitor or radioactive source is administered directly into a body tissue.

### Claim 209

A composition, comprising a radioactive source and a cell-cycle inhibitor.

### Claim 210 (depends on 209)

The composition according to claim 209 wherein said radioactive source is selected from the group consisting of activity I125, Pd103 and Ir192; Co60, Cs137, and Ru106.

### Claim 211 (depends on 209)

The composition according to claim 209 wherein said cell-cycle inhibitor is paclitaxel or an analogue or derivative thereof.

### Claim 212 (depends on 209)

The composition according to claim 209 wherein said cell-cycle inhibitor is camptothecin, or an analogue or derivative thereof.

### Claim 213 (depends on 209)

The composition according to claim 209, further comprising a polymer.

### Claim 214 (depends on 213)

The composition according to claim 213 wherein said polymer is a non-biodegradable polymer.

### Claim 215 (depends on 213)

The composition according to claim 213 wherein said polymer is a biodegradable polymer.

### Claim 216 (depends on 213)

The composition according to claim 213 wherein said polymer comprises poly (caprolactone), polyurethane, or, poly (ethylene vinyl acetate).

### Claim 217 (depends on 213)

The composition according to claim 213 wherein said polymer comprises poly (lactic acid).

### Claim 218 (depends on 213)

The composition according to claim 213 wherein said polymer comprises a copolymer of poly (caprolactone) and poly (lactic acid).

### Claim 219 (depends on 213)

The composition according to claim 213 wherein said polymer comprises MePEG.

### Claim 220

A method for treating a hyperproliferative disease of the prostate, comprising administering to the prostate a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease of the prostate is treated.

### Claim 221 (depends on 220)

The method according to claim 220 wherein said hyperproliferative disease of the prostate is prostate cancer.

### Claim 222 (depends on 220)

The method according to claim 220 wherein said hyperproliferative disease of the prostate is benign prostatic hypertrophy.

### Claim 223 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 224 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 225 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 226 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 227 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive stent.

### Claim 228 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor and radioactive source is delivered transurethrally through a drug-delivery balloon or catheter.

### Claim 229 (depends on 220)

The method according to claim 220 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 230 (depends on 220)

The method according to claim 220 wherein said cell-cycle inhibitor comprises at least one taxane, toposiomerase inhibitor, vinca alkaloid, alkalating agent, or, estramustine.

### Claim 231

A method for treating a hyperproliferative disease of the anorectum, comprising administering to the anorectum a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease of the anorectum is treated.

### Claim 232 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor is administered to the rectal mucosa.

### Claim 233 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive capsule.

### Claim 234 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive capsule.

### Claim 235 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 236 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 237 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 238 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 239 (depends on 231)

The method according to claim 231 wherein said cell cycle inhibitor is injected interstitially.

### Claim 240 (depends on 231)

The method according to claim 231 wherein said cell-cycle inhibitor comprises at least one taxane, platinum, toposiomerase inhibitor, alkalating agent, mitomycin, or leucovorine.

### Claim 241

A method for treating a hyperproliferative disease of the bladder or urinary tract, comprising administering to the bladder or urinary tract a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 242 (depends on 241)

The method according to claim 241 wherein said hyperproliferative disease is bladder cancer.

### Claim 243 (depends on 241)

The method according to claim 241 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 244 (depends on 241)

The method according to claim 241 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 245 (depends on 241)

The method according to claim 241 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 246 (depends on 241)

The method according to claim 241 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 247 (depends on 241)

The method according to claim 241 wherein said cell cycle inhibitor is injected interstitially.

### Claim 248 (depends on 241)

The method according to claim 241 wherein said cell-cycle inhibitor comprises at least one taxane, ethyleneimine, anthracyclines, antimetabolites, vinca alkaloids, platinum or, mitomycin.

### Claim 249

A method for treating a hyperproliferative disease of the eye, comprising administering to the eye a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 250 (depends on 249)

The method according to claim 249 wherein said hyperproliferative disease of the eye is uveal melanoma.

### Claim 251 (depends on 249)

The method according to claim 249 wherein said hyperproliferative disease of the eye is retinoblastoma.

### Claim 252 (depends on 249)

The method according to claim 249 wherein said cell cycle inhibitor and radioactive source is administered via a surface eye mold.

### Claim 253 (depends on 249)

The method according to claim 249 wherein said cell cycle inhibitor is injected intravitreally, or, administered via a shunt.

### Claim 254 (depends on 249)

The method according to claim 249 wherein said cell cycle inhibitor is administered in a paste, film, gel, or, spray.

### Claim 255 (depends on 249)

The method according to claim 249 wherein said cell-cycle inhibitor comprises at least one taxane, vinca alkaloid, alkylating agent, anthracycline, platinum, nitrogen mustard or, topoisomerase inhibitor.

### Claim 256

A method for treating a hyperproliferative disease of the brain, comprising administering to the brain a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 257 (depends on 256)

The method according to claim 256 wherein said hyperproliferative disease of the brain is a malignant glioma.

### Claim 258 (depends on 256)

The method according to claim 256 wherein said hyperproliferative disease of the bra in is an astrocytoma.

### Claim 259 (depends on 256)

The method according to claim 256 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 260 (depends on 256)

The method according to claim 256 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 261 (depends on 256)

The method according to claim 256 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 262 (depends on 256)

The method according to claim 256 wherein said cell cycle inhibitor is injected interstitially.

### Claim 263 (depends on 256)

The method according to claim 256 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 264 (depends on 256)

The method according to claim 256 wherein said cell-cycle inhibitor comprises at least one taxane, nitrosurea, tetrazine, vinca alkaloid, platinum, topoisomerase inhibitor, antimetabolites, or, leucovorin.

### Claim 265

A method for treating a hyperproliferative disease of the breast, comprising administering to the breast a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease of the breast is treated.

### Claim 266 (depends on 265)

The method according to claim 265 wherein said hyperproliferative disease of the breast is breast cancer.

### Claim 267 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 268 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 269 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 270 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 271 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor is injected interstitially.

### Claim 272 (depends on 265)

The method according to claim 265 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 273 (depends on 265)

The method according to claim 265 wherein said cell-cycle inhibitor comprises at least one taxane, anthracycline, alkylating agent, antimetabolite, vinca alkaloid, platinum, nitrogen mustard, gemcitabine, or, mitomycin.

### Claim 274

A method for treating a hyperproliferative disease of the esophagus, comprising administering to the esophagus a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 275 (depends on 274)

The method according to claim 274 wherein said hyperproliferative disease of the esophagus is esophageal cancer.

### Claim 276 (depends on 274)

The method according to claim 274 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive stent.

### Claim 277 (depends on 274)

The method according to claim 274 wherein said cell cycle inhibitor is administered via a balloon or catheter.

### Claim 278 (depends on 274)

The method according to claim 274 wherein said cell-cycle inhibitor comprises at least one taxane, alkalating agent, platinum, or, mitomycin.

### Claim 279

A method for treating a hyperproliferative disease of the genital tract, comprising administering to the genital tract a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 280 (depends on 279)

The method according to claim 279 wherein said hyperproliferative disease of the genital tract is penile cancer.

### Claim 281 (depends on 279)

The method according to claim 279 wherein said hyperproliferative disease of the genital tract is vaginal cancer.

### Claim 282 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 283 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 284 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 285 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 286 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor administered interstitially.

### Claim 287 (depends on 279)

The method according to claim 279 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 288 (depends on 279)

The method according to claim 279 wherein said cell-cycle inhibitor comprises at least one taxane, vinca alkaloid, antimetabolite, platinum or, alkylating agent.

### Claim 289

A method for treating a hyperproliferative disease of the uterus or cervix, comprising administering to the uterus or cervix a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 290 (depends on 289)

The method according to claim 289 wherein said hyperproliferative disease is endometrial cancer.

### Claim 291 (depends on 289)

The method according to claim 289 wherein said hyperproliferative disease is cervical cancer.

### Claim 292 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive capsule.

### Claim 293 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive capsule.

### Claim 294 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor is administered to the surface of the cervix or endometrium.

### Claim 295 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 296 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 297 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 298 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor is injected interstitially.

### Claim 299 (depends on 289)

The method according to claim 289 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 300 (depends on 289)

The method according to claim 289 wherein said cell-cycle inhibitor comprises at least one taxane, platinum, alkylating agent, nitrogen mustard, topoisomerase inhibitor, anthracycline, or, estramustine.

### Claim 301

A method for treating a hyperproliferative disease of the liver or bile duct, comprising administering to the liver or bile duct a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 302 (depends on 301)

The method according to claim 301 wherein said hyperproliferative disease is liver cancer.

### Claim 303 (depends on 301)

The method according to claim 301 wherein said hyperproliferative disease is a biliary tumor.

### Claim 304 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 305 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 306 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 307 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 308 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive stent.

### Claim 309 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor and radioactive source is delivered through a drug-delivery balloon or catheter, or injected interstitially.

### Claim 310 (depends on 301)

The method according to claim 301 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 311 (depends on 301)

The method according to claim 301 wherein said cell-cycle inhibitor comprises at least one taxane, anthracyline, platinum, alkylating agent, gemcitabine, mitomycin, or, floxuridine.

### Claim 312

A method for treating a hyperproliferative disease of the lung, comprising administering to the lung a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 313 (depends on 312)

The method according to claim 312 wherein said hyperproliferative disease is lung cancer.

### Claim 314 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 315 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 316 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 317 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 318 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive stent.

### Claim 319 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor and radioactive source is delivered through a drug-delivery balloon or catheter.

### Claim 320 (depends on 312)

The method according to claim 312 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 321 (depends on 312)

The method according to claim 312 wherein said cell-cycle inhibitor comprises at least one taxane, topoisomerase inhibitor, vinca alkaloid, platinum, alkylating agent, anthracycline, nitrogen mustard, antimetabolite, nitrosurea, mitomycin, or, gemcitabine.

### Claim 322

A method for treating a hyperproliferative disease of the pancreas, comprising administering to the pancreas a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 323 (depends on 322)

The method according to claim 322 wherein said hyperproliferative disease is pancreatic cancer.

### Claim 324 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 325 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 326 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 327 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 328 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor is administered interstitially.

### Claim 329 (depends on 322)

The method according to claim 322 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 330 (depends on 322)

The method according to claim 322 wherein said cell-cycle inhibitor comprises at least one taxane, anthracycline, nitrogen mustard, tetrazine, platinum, antimetabolite, or, vinca alkaloid.

### Claim 331

A method for treating soft-tissue sarcomas, comprising administering to a soft-tissue sarcoma a cell cycle inhibitor and a radioactive source, such that sarcoma is treated.

### Claim 332 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 333 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 334 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 335 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 336 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor is administered interstitially.

### Claim 337 (depends on 331)

The method according to claim 331 wherein said cell cycle inhibitor is administered in a paste, film, or, spray.

### Claim 338 (depends on 331)

The method according to claim 331 wherein said cell-cycle inhibitor comprises at least one taxane, anthracycline, nitrogen mustard, tetrazine, platinum, antimetabolite, or, vinca alkaloid.

### Claim 339

A method for treating a hyperproliferative disease of the skin, comprising administering to the skin a cell cycle inhibitor and a radioactive source, such that said hyperproliferative is treated.

### Claim 340 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor is administered topically, subcutaneously, or intradermally.

### Claim 341 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor and radioactive source are administered via a surface mold, or, via a transdermal patch.

### Claim 342 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 343 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 344 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 345 (depends on 339)

The method according to claim 339 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 346 (depends on 339)

The method according to claim 339 wherein said cell-cycle inhibitor comprises at least one taxane, alkylating agent, tetrazine, or, nitrosurea.

### Claim 347

A method for treating a hyperproliferative disease of the head or neck, comprising administering to the head or neck a cell cycle inhibitor and a radioactive source, such that said hyperproliferative disease is treated.

### Claim 348 (depends on 347)

The method according to claim 347 wherein said hyperproliferative disease is a tumor of the tongue, mouth, lip, or, nasopharnyx.

### Claim 349 (depends on 347)

The method according to claim 347 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive seed.

### Claim 350 (depends on 347)

The method according to claim 347 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive suture.

### Claim 351 (depends on 347)

The method according to claim 347 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor loaded radioactive suture.

### Claim 352 (depends on 347)

The method according to claim 347 wherein said cell cycle inhibitor and radioactive source is a cell cycle inhibitor coated radioactive wire.

### Claim 353 (depends on 347)

The method according to claim 347 wherein said cell cycle inhibitor is administered interstitially.

### Claim 354 (depends on 347)

The method according to claim 347 wherein said cell-cycle inhibitor comprises at least one polypeptide, taxane, antimetabolite, platinum, alkylating agent, nitrogen mustard, anthracycline, or vinca alkaloid.

### Claim 355

A radioactive polymer comprising a radioactive monomer and a non-radioactive monomer.

### Claim 356 (depends on 355)

The radioactive polymer according to claim 355 wherein said source of radiation is selected from the group consisting of I125, Pd103, Ir192, Co60, Cs137, Au198 and Ru106.

### Claim 357 (depends on 355)

The radioactive polymer according to claim 355 wherein said polymer is formed into a solid, porous material, slurry, gel or spray
